Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of AZD2171 in Patients With Recurrent or Stage IV Malignant Melanoma

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase II Treatment Active 18 and over NCI PMH-PHL-038 7137, NCT00243061

Trial Description

Purpose:

AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Measurable disease
• No brain metastases
• More than 4 weeks since radiation therapy or surgery
• No previous chemotherapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive AZD2171 by mouth once a day. Treatment may continue for as long as benefit is shown.

After finishing treatment, patients will be evaluated periodically.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Princess Margaret Hospital

Elaine McWhirter, MD, MSC, FRCPC, Protocol chair		Ph: 905-387-9495 ext. 67559

U.S.A.
Illinois
	Chicago
	University of Chicago Cancer Research Center
		Clinical Trials Office - University of Chicago Cancer Research Center	Ph:  773-834-7424
Canada
Ontario
	Hamilton
	Margaret and Charles Juravinski Cancer Centre
		Sebastien Hotte, MD	Ph:  905-387-9495, ext. 64784
			Email: sebastien.hotte@hrcc.on.ca
	London
	London Regional Cancer Program at London Health Sciences Centre
		Jawaid Younus, MD	Ph:  519-685-8600 ext. 53327
			Email: jawaid.younus@lhsc.on.ca
	Ottawa
	Ottawa Hospital Regional Cancer Centre - General Campus
		Shailendra Verma, MD, FRCP	Ph:  613-737-7700 ext. 70174 888-627-5346
			Email: sverma@ottawahospital.on.ca

Registry Information
Official Title		A Phase II Study of AZD2171 in Previously Untreated Patients with Metastatic or Recurrent Malignant Melanoma
Trial Start Date		2006-01-30
Trial Completion Date		2007-06-09 (estimated)
Registered in ClinicalTrials.gov		NCT00243061
Date Submitted to PDQ		2005-08-29
Information Last Verified		2007-09-21
NCI Grant/Contract Number		CM62203, CM62201